Recent progress in percutaneous coronary intervention: Evolution of the drug-eluting stents, focus on the XIENCE v drug-eluting stent

Coronary Artery Disease

Volumn 21, Issue 1, 2010, Pages 46-56

  Doostzadeh, Julie ^a   Clark, Lee N ^a   Bezenek, Susan ^a   Pierson, Wesley ^a   Sood, Poornima R ^a   Sudhir, Krishnankutty ^a  

^a ABBOTT VASCULAR   (United States)

Author keywords

Bare metal stents; Clinical trial design; Coronary stent; Percutaneous coronary intervention; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN; TICLOPIDINE; ZOTAROLIMUS;

BARE METAL STENT; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG WITHDRAWAL; EVOLUTION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMPLANTATION; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SAFETY; STENT THROMBOSIS; TREATMENT WITHDRAWAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; METALS; MYOCARDIAL INFARCTION; PROSTHESIS DESIGN; RISK ASSESSMENT; SIROLIMUS; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 75149186970     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328333f550     Document Type: Review

References (85)

1. Barragan P, Rieu R, Garitey V, Roquebert PO, Sainsous J, Silvestri M, et al. Elastic recoil of coronary stents: a comparative analysis. Catheter Cardiovasc Interv 2000; 50:112-119.
2. Ormiston JA, Dixon SR,Webster MW, Ruygrok PN, Stewart JT, Minchington I, et al. Stent longitudinal flexibility: a comparison of 13 stent designs before and after balloon expansion. Catheter Cardiovasc Interv 2000; 50:120-124.
3. Ku DN, Giddens DP, Zarins CK, Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis 1985; 5:293-302.
4. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999; 282:2035-2042.
5. Kastrati A, Dirschinger J, Boekstegers P, Elezi S, Schuhlen H, Pache J, et al. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1147 unselected patients. Catheter Cardiovasc Interv 2000; 50:290-297.
6. Hoffmann R, Jansen C, Konig A, Haager PK, Kerckhoff G, Vom Dahl J, et al. Stent design related neointimal tissue proliferation in human coronary arteries; an intravascular ultrasound study. Eur Heart J 2001; 22:2007-2014.
7. Kastrati A, Mehilli J, Dirschinger J, Pache J, Ulm K, Schuhlen H, et al. Restenosis after coronary placement of various stent types. Am J Cardiol 2001; 87:34-39.
8. McLean DR, Eiger NL. Stent design: implications for restenosis. Rev Cardiovasc Med 2002; 3 (Suppl 5):S16-S22.
9. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 1995; 91:2995-3001.
10. Yoshitomi Y, Kojima S, Yano M, Sugi T, Matsumoto Y, Saotome M, et al. Does stent design affect probability of restenosis? A randomized trial comparing Multilink stents with GFX stents. Am Heart J 2001; 142:445-451.
11. Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A, et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol 2002; 40:403-409.
12. Serruys PW, Rensing B. Handbook of coronary stents, London: Martin Dunitz; Distributed in the USA by Fulfilment Center Taylor and Francis (Kentucky, USA); 1998.
13. Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED, et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003; 92:463-466.
14. Van der Hoeven BL, Pires NM,Warda HM, Oemrawsingh PV, van Vlijmen BJ, Quax PH, et al. Drug-eluting stents: results, promises and problems. Int J Cardiol 2005; 99:9-17.
15. Ong AT, Serruys PW. Technology insight: an overview of research in drug-eluting stents. Nat Clin Pract Cardiovasc Med 2005; 2:647-658.
16. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001; 59:227-248.
17. Winslow RD, Sharma SK, Kim MC. Restenosis and drug-eluting stents. Mt Sinai J Med 2005; 72:81-89.
18. Tanabe K, Regar E, Lee CH, Hoye A, Van der Giessen WJ, Serruys PW. Local drug delivery using coated stents: new developments and future perspectives. Curr Pharm Des 2004; 10:357-367.
19. Wong A, Chan C. Drug-eluting stents: the end of restenosis? Ann Acad Med Singapore 2004; 33:423-431.
20. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52:333-342.
21. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496-501.
22. Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, RutschW, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489-495.
23. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann F-J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcoume (ISAR-STEREO) trial. Circulation 2001; 103:2816-2821.
24. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41:1283-1288.
25. Rittersma SZ, De Winter RJ, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Impact of strut thickness on late luminal loss after coronary artery stent placement. Am J Cardiol 2004; 93:477-480.
26. Sketch MH Jr, Ball M, Rutherford B, Popma JJ, Russell C, Kereiakes DJ. Evaluation of the medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol 2005; 95:8-12.
27. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004; 44:733-739.
28. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009; 119:680-686.
29. Endeavor Clinical Programs. http://www.endeavorstent.com/html/us/ hcp-end-clinicaldata.html
30. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Clark MR, Cohen BM, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 2006; 47:1350-1355.
31. Stone GW. 2-Year clinical results of the TAXUS-IV Trial. TCT 2004.
32. Direction For Use: TAXUS Express2 and TAXUS Express2 Atom Monorail, Over-The-Wire Paclitaxel-Eluting Coronary Stent System. Boston Scientific 2008; http://www.bostonscientific.com
33. Serruys PW. SPIRIT FIRST clinical trial: A 180-day clinical evaluation of the Guidant MULTI-LINK VISION everolimus-eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. Circulation 2004; 110 (17 Suppl S):565.
34. Serruys P, Ruygrok P, Neuzner JJO, Piek JJ, Seth A, Schofer JJ, et al. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2006; 2:286-294.
35. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299:1903-1913.
36. Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, et al. SPIRIT IV Trial design: a large-scale randomized comparison of everolimuseluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J 2009; 158:520.e2-526.e2. (Accepted).
37. Gershlick A, Kandzari DE, Leon MB, Wijns W, Meredith IT, Fajadet J, et al. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1317 patients. Am J Cardiol 2007; 100:45M-55M.
38. Leon M. The ENDEAVOR IV: a randomized comparison of a zotarolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease coronary disease. TCT 2007.
39. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-1780.
40. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323.
41. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362:1093-1099.
42. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43:1110-1115.
43. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107:38-42.
44. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow-and moderaterelease polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108:788-794.
45. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294:1215-1223.
46. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005; 112:3306-3313.
47. Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 2007; 28:2578-2582.
48. Stone G. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-231.
49. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45:1193-1200.
50. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, et al. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 2007; 49:1676-1683.
51. Direction For Use: TAXUS Liberte, TAXUS Liberte Atom, TAXUS Liberte Long Monorail, Over-The-Wire Paclitaxel-Eluting Coronary Stent System. Boston Scientific 2009; http://www.bostonscientific.com
52. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimuseluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114:798-806.
53. Leon M. ENDEAVOR IV: Two-year follow-up from a prospective randomized trial comparing a zotarolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease. TCT 2008 2008.
54. Lasave LI, Costa Jde R Jr, Abizaid AA, Feres F, Tanajura LF, Staico R, et al. A three-dimensional intravascular ultrasound comparison between the new zotarolimus-eluting stent (ZoMaxx) and the non-drug-eluting TriMaxx stent. J Invasive Cardiol 2007; 19:303-308.
55. Joner M, Quee SC, Coleman L, Skorija K, Wilson P, Kolodgie FD, et al. Abstract 2460: competitive comparison of reendothelialization in drug eluting stents. Circulation 2006; 114:(Suppl 2):506.
56. Tsuchida K, Piek JJ, Neumann FJ, Van der GiessenWJ,Wiemer M, Zeiher AM, et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowing (The SPIRIT FIRST Trial). EuroIntervention 2005; 1:266-272.
57. Beijk M, Neumann F-J, Wiemer M, Grube E, Haase J, Thuesen L, et al. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial). EuroIntervention 2007; 3:206-212.
58. Serruys PW. SPIRIT II Study: a clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. J Am Coll Cardiol 2009; 53:A11.
59. Serruys PW, Ong AT, Piek JJ, Neumann F-J, Van der GiessenWJ,Weimer M, et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005; 1:58-65.
60. Kukreja N, Onuma Y, Serruys PW. Xience V everolimus-eluting coronary stent. Expert Rev Med Devices 2009; 6:219-229.
61. Onuma Y, Serruys PW, Kukreja N, Stone GW, investigators ObotSIaI. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: pooled analysis of two-year clinical follow-up from the SPIRIT II and III Trials. J Am Coll Cardiol 2009; 53:A9-A10.
62. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005; 45:308-311.
63. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al. Sirolimus vs. paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295:895-904.
64. Windecker S, Remondino A, Eberli FR, Juni P, Raber L,Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353:653-662. (Pubitemid 41175673)
65. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115:2344-2351.
66. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45:954-959.
67. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360:1946-1959.
68. Ellis SGCA, Grube E, Popma J, Koglin J, Dawkins KD, Stone GW. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3445 patients followed for up to 3 years. J Am Coll Cardiol 2007; 49:1043-1051.
69. Lemos PA, Lee CH, Degertekin M, Saia F, Tanabe K, Arampatzis CA, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003; 41:2093-2099.
70. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol 2005; 45:941-946.
71. Pasceri V, Granatelli A, Pristipino C, Pelliccia F, Pironi B, Richichi G. A randomized trial of a rapamycin-eluting stent in acute myocardial infarction: preliminary results. Am J Cardiol 2003; 92 (Suppl 6A):1L.
72. Park SJ, Shim WH, Ho AE, Raizner SW, Park MK, Hong CW, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348:1537-1545.
73. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113:1434-1441.
74. Dobies D, Lasala JM, Cox DA, Mann T, Armstrong B, Koglin J, et al. Predictors of stent thrombosis in real-world use of the TAXUS Express2 paclitaxel-eluting stent: insights from the ARRIVE registry to 2 years. PCR 2007.
75. Lasala JM, Stone GW, Dawkins KD, Serruys PW, Colombo A, Grube E, et al. An overview of the TAXUS Express, paclitaxel-eluting stent clinical trial program. J Interv Cardiol 2006; 19:422-431.
76. Pinto Slottow TL, Waksman R. Overview of the 2007 food and drug administration circulatory system devices panel meeting on the endeavor zotarolimus-eluting coronary stent. Circulation 2008; 117:1603-1608.
77. Aoki J, Rodriguez-Granillo GA, Serruys PW. Emergent strategies in interventional cardiology. Rev Esp Cardiol 2005; 58:962-973.
78. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimuseluting coronary stent. Catheter Cardiovasc Interv 2007; 69:128-131.
79. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L,Webster MW, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371:899-907.
80. Reva Medical Inc. Website. http://www.teamreva.com/heart-stents-tech.html
81. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 2004; 109:2692-2697. (Pubitemid 38737912)
82. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9:702-712.
83. James SK, Stenestrand U, Lindback J, Carlsson J, Schersten F, Nilsson T, et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009; 360:1933-1945.
84. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Kereiakes DJ, et al. TCT 2009 abstract: a large-scale randomized comparison of everolimuseluting and paclitaxel-eluting stents: one-year clinical outcomes from the SPIRIT IV trial. Am J Cardiol 2009; 140:XV.
85. Smits PC, Sheikjoesoef K,Wassing J, McFadden E, van Mieghem CAG, Kedhi E. TCT 2009 abstract: Compare trial. A prospective, randomized trial of everolimus-eluting vs. paclitaxel-eluting stents. Am J Cardiol 2009; 140:XV.